Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

被引:42
作者
Farngren, J. [1 ]
Persson, M. [2 ]
Schweizer, A. [3 ]
Foley, J. E. [4 ]
Ahren, B. [1 ]
机构
[1] Lund Univ, Dept Clin Sci, S-22184 Lund, Sweden
[2] Lund Univ, Dept Clin Sci Malmo, Lund, Sweden
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
基金
瑞典研究理事会;
关键词
DPP-4; inhibition; glucagon; hypoglycaemia; insulin-treated; type; 2; diabetes; vildagliptin; IMPROVES GLYCEMIC CONTROL; GLP-1 RECEPTOR AGONISTS; REDUCES GLUCAGON; GLUCOSE CONTROL; CELL-FUNCTION; SECRETION; COMBINATION; COUNTERREGULATION; METFORMIN; INHIBITOR;
D O I
10.1111/dom.12284
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To determine the effects of dipeptidyl peptidase 4 (DPP-4) inhibition on glucagon dynamics in patients with insulin-treated type 2 diabetes (T2D). Methods: The study was a single-centre, double-blind, randomized, placebo controlled crossover study in patients with T2D, mean age 59 +/- 6 (s.d.) years and mean haemoglobin A1c 7.7 +/- 0.8%, treated with exogenous insulin with or without oral antihyperglycaemic agents. Patients received vildagliptin (50 mg BID) or placebo as add-on to insulin for 4 weeks in random order with a 4-week washout in-between. On day 28 of the respective treatment, patients were served a standard meal (500 kcal) followed by a hyperinsulinaemic hypoglycaemic clamp (target 2.5 mmol/l) and a subsequent food re-challenge (700 kcal). The completers population (n=29) was analysed. Results: Glucose levels were lower with vildagliptin than with placebo during the meal [areas under the curve (AUC) 1.23 +/- 0.07 vs. 1.46 +/- 0.05 mol/l min, P < 0.001] and similar between the groups during the clamp. During the meal, glucagon levels were lower with vildagliptin (AUC 1.98 +/- 0.15 vs. 2.15 +/- 0.17 nmol/l min, P = 0.016). In contrast, the glucagon counter-regulation to the insulin-induced hypoglycaemia was sustained by vildagliptin (6.05 +/- 1.20 pmol/l during vildagliptin vs. 6.94 +/- 1.09 pmol/l during placebo, NS). During the food re-challenge after hypoglycaemia, glucagon levels were, again, significantly lower after vildagliptin (AUC 1.30 +/- 0.11 vs. 1.52 +/- 0.12 nmol/lmin, P < 0.039). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels were significantly elevated by vildagliptin compared to placebo during meal, hypoglycaemia and food re-challenge. Conclusions: Vildagliptin action to block GLP-1 and GIP inactivation by DPP-4 improves glucagon dynamics during hypoglycaemia, hyperglycaemia and food re-challenge.
引用
收藏
页码:812 / 818
页数:7
相关论文
共 34 条
[1]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[2]   Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans [J].
Ahren, B. ;
Schweizer, A. ;
Dejager, S. ;
Villhauer, E. B. ;
Dunning, B. E. ;
Foley, J. E. .
DIABETES OBESITY & METABOLISM, 2011, 13 (09) :775-783
[3]  
Ahren B, 2013, J EUR DIABET NURSING, V10, P31, DOI DOI 10.1002/EDN.221]
[4]   Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes [J].
Ahren, Bo .
VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 :155-163
[5]   Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes [J].
Ahren, Bo ;
Schweizer, Anja ;
Dejager, Sylvie ;
Dunning, Beth E. ;
Nilsson, Peter M. ;
Persson, Margaretha ;
Foley, James E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (04) :1236-1243
[6]   Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature [J].
Balena, R. ;
Hensley, I. E. ;
Miller, S. ;
Barnett, A. H. .
DIABETES OBESITY & METABOLISM, 2013, 15 (06) :485-502
[7]   Insulin as a physiological modulator of glucagon secretion [J].
Bansal, Pritpal ;
Wang, Qinghua .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (04) :E751-E761
[8]  
BOLLI GB, 1984, J CLIN INVEST, V73, P1532, DOI 10.1172/JCI111359
[9]   Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].
Bosi, Emanuele ;
Camisasca, Riccardo Paolo ;
Collober, Carole ;
Rochotte, Erika ;
Garber, Alan J. .
DIABETES CARE, 2007, 30 (04) :890-895
[10]   Glucose-Dependent Insulinotropic Polypeptide A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans [J].
Christensen, Mikkel ;
Vedtofte, Louise ;
Holst, Jens J. ;
Vilsboll, Tina ;
Knop, Filip K. .
DIABETES, 2011, 60 (12) :3103-3109